Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol

Abstract

IntroductionEighty per cent of the sexually active population will get human papillomavirus (HPV) infection, which is the most prevalent sexually transmitted disease worldwide. Persistence of high-grade HPV infection may evolve to a cervical intraepithelial neoplasia (CIN), and these lesions may be precursors of cervical cancer. However, this progression can be prevented by the administration of therapeutic vaccines which use the main oncoproteins responsible for cancer development in an attempt to trigger a more specific and effective immunological response against this disorder. We aim to evaluate the safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade CIN 2/3 associated with HPV.Methods and analysisA systematic review of clinical trials will be undertaken. Medline, Excerpta Medica Database, Cochrane Central Register of Controlled Trials, Web of Science, Latin American and Caribbean Health Sciences Literature, Scientific Electronic Library Online and Scopus will be searched, with no restriction regarding publication date. Primary outcomes will include measures related to safety, efficacy and the immunogenicity of the therapeutic vaccines used in these patients. Study selection will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Methodological appraisal of the studies will be assessed by the Cochrane Risk-of-Bias Tool for randomised controlled trials, and the quality evidence of the risk of bias in single studies will be evaluated by Grading of Recommendations Assessment, Development and Evaluation. A narrative synthesis will be done for all included studies. Outcomes will be analysed according to the subgroups of HPV type, CIN grade, route of vaccine administration and vaccine type. Also, if sufficient data are available, a meta-analysis will be conducted. The effect sizes will be generated using Hedges’ g score for both fixed and random effect models. I2statistics will be used to assess heterogeneity and identify their potential sources.Ethics and disseminationEthical approval is not required as primary data will not be collected. Findings will be disseminated widely via peer-reviewed publication and in different media, for example, conferences, congresses or symposia.PROSPERO registration numberCRD42017077428.

Effectiveness of hospital clowns for symptom management in paediatrics: systematic review of randomised and non-randomised controlled trials

“…If the disagreement persisted, a third reviewer (ETN) made a final decision. Using standardised forms, 40 41 42 43 two authors (LCL-J and EB) independently extracted data, and clarifications on the following four areas were requested from the study’s authors when necessary:…”

School reopening and risks accelerating the COVID-19 pandemic: A systematic review and meta-analysis protocol

“…First, we will screen for controlled descriptors, for instance, MeSH terms, Emtree terms, and their synonyms, as well as keywords will be identified. The Boolean operators “AND” and “OR” will be employed to combine the descriptors [ 39 , 41 , 42 ]. The preliminary pilot search strategy combining MeSH terms, synonyms (entry terms) as well as keywords that will be used in MEDLINE/PubMed is shown in Table 2 .…”

“…In addition, primary studies that did not meet the inclusion criteria will be excluded according to the reasons for exclusion. The two review authors (LCLJ and PCS) will perform data extraction for each included study based on forms published previously [ 39 , 41 – 44 ]. The expected completion date for this systematic review is September 30, 2021, due to the urgency to bring this evidence to light, in the current scenario in which the delta variant is spreading rapidly in several countries.…”

Efficacy of the complementary therapies in the management of cancer pain in palliative care: A systematic review

“…Figure 1 shows the final search strategy processed in the respective databases. (TS || =("Adult" AND "Cancer Patients" OR "Advanced Cancer Patients" AND "Neoplasms" OR "Cancer" AND "Palliative Care" OR "Palliative Medicine" OR "Hospices") AND TS=("Complementary Therapies" OR "Therapies, Complementary" OR "Complementary Medicine" OR "Alternative Medicine" OR "Alternative Therapies" OR "Non-pharmacological Interventions") AND TS=("Cancer Pain" OR "Cancer-Associated Pain" "OR "Cancer-Related Pain" OR "Neoplasm Related Pain" OR "Tumor Associated Pain" OR "Oncological Pain" OR "Oncology Pain") AND TS=("Randomized Controlled Trial" OR "Controlled Clinical Trial" OR "Clinical Trial" OR "Random Allocation" OR "Double-blind Method" OR "Single-blind Method")) Data were extracted based on pre-established tools (29)(30)(31) and included four domains: I) Identification of the study, with data such as the title of the article, impact factor of the journal, country of the authors of the study, year of publication, host institution of the study (hospital;…”